Which has preferable valuation and earnings, BNTC or BCAX?

Benitec Biopharma is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is BNTC or BCAX more profitable?

Benitec Biopharma's return on equity of -34.82% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Benitec Biopharma N/A -34.82% -34.11% Bicara Therapeutics N/A -35.89% -33.78%

Benitec Biopharma (BNTC) Competitors

$13.63 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.80 -0.83 (-6.05%)

As of 09:00 AM Eastern

Compare

BNTC vs. BCAX, IMCR, SNDX, ZYME, and ANAB

Should you buy Benitec Biopharma stock or one of its competitors? MarketBeat compares Benitec Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Benitec Biopharma include Bicara Therapeutics (BCAX), Immunocore (IMCR), Syndax Pharmaceuticals (SNDX), Zymeworks (ZYME), and AnaptysBio (ANAB). These companies are all part of the "biotechnology" industry.

How does Benitec Biopharma compare to Bicara Therapeutics?

Benitec Biopharma (NASDAQ:BNTC) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Benitec Biopharma is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Bicara Therapeutics had 4 more articles in the media than Benitec Biopharma. MarketBeat recorded 4 mentions for Bicara Therapeutics and 0 mentions for Benitec Biopharma. Bicara Therapeutics' average media sentiment score of 0.17 beat Benitec Biopharma's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
Bicara Therapeutics	Neutral

52.2% of Benitec Biopharma shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Benitec Biopharma's return on equity of -34.82% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Benitec Biopharma currently has a consensus price target of $24.80, suggesting a potential upside of 81.95%. Bicara Therapeutics has a consensus price target of $30.27, suggesting a potential upside of 7.89%. Given Benitec Biopharma's higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Benitec Biopharma has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Summary

Bicara Therapeutics beats Benitec Biopharma on 8 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Immunocore currently has a consensus price target of $57.29, indicating a potential upside of 68.49%. Benitec Biopharma has a consensus price target of $24.80, indicating a potential upside of 81.95%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Benitec Biopharma	N/A	-34.82%	-34.11%

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Immunocore has higher revenue and earnings than Benitec Biopharma. Immunocore is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.32	-$35.51M	-$0.37	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

In the previous week, Immunocore had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 12 mentions for Immunocore and 0 mentions for Benitec Biopharma. Immunocore's average media sentiment score of 0.27 beat Benitec Biopharma's score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Overall Sentiment
Immunocore	Neutral
Benitec Biopharma	Neutral

84.5% of Immunocore shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunocore beats Benitec Biopharma on 11 of the 16 factors compared between the two stocks.

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Benitec Biopharma has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Benitec Biopharma's return on equity of -34.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Benitec Biopharma	N/A	-34.82%	-34.11%

Syndax Pharmaceuticals currently has a consensus price target of $42.36, suggesting a potential upside of 107.66%. Benitec Biopharma has a consensus price target of $24.80, suggesting a potential upside of 81.95%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Syndax Pharmaceuticals had 26 more articles in the media than Benitec Biopharma. MarketBeat recorded 26 mentions for Syndax Pharmaceuticals and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.00 beat Syndax Pharmaceuticals' score of -0.32 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Syndax Pharmaceuticals	Neutral
Benitec Biopharma	Neutral

Syndax Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Benitec Biopharma has lower revenue, but higher earnings than Syndax Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.49	-$285.42M	-$2.51	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

Syndax Pharmaceuticals and Benitec Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to Zymeworks?

Benitec Biopharma (NASDAQ:BNTC) and Zymeworks (NASDAQ:ZYME) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Benitec Biopharma has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Benitec Biopharma's return on equity of -34.82% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Zymeworks	-405.31%	-72.30%	-37.18%

Benitec Biopharma has higher earnings, but lower revenue than Zymeworks. Benitec Biopharma is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Zymeworks	$105.96M	15.76	-$81.13M	-$2.02	N/A

In the previous week, Zymeworks had 16 more articles in the media than Benitec Biopharma. MarketBeat recorded 16 mentions for Zymeworks and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.00 beat Zymeworks' score of -0.01 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
Zymeworks	Neutral

Benitec Biopharma presently has a consensus target price of $24.80, indicating a potential upside of 81.95%. Zymeworks has a consensus target price of $38.22, indicating a potential upside of 62.37%. Given Benitec Biopharma's higher possible upside, equities analysts plainly believe Benitec Biopharma is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Summary

Zymeworks beats Benitec Biopharma on 9 of the 16 factors compared between the two stocks.

How does Benitec Biopharma compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

52.2% of Benitec Biopharma shares are held by institutional investors. 31.5% of AnaptysBio shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Benitec Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.15	-$13.23M	-$1.08	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

AnaptysBio has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Benitec Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Benitec Biopharma	N/A	-34.82%	-34.11%

AnaptysBio presently has a consensus target price of $82.00, indicating a potential upside of 44.85%. Benitec Biopharma has a consensus target price of $24.80, indicating a potential upside of 81.95%. Given Benitec Biopharma's higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, AnaptysBio had 3 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for AnaptysBio and 0 mentions for Benitec Biopharma. AnaptysBio's average media sentiment score of 0.45 beat Benitec Biopharma's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Overall Sentiment
AnaptysBio	Neutral
Benitec Biopharma	Neutral

Summary

AnaptysBio beats Benitec Biopharma on 11 of the 15 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$468.19M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-11.96	9.02	270.57	25.05
Price / Sales	N/A	1,291.29	659.56	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	3.67	17.52	11.20	6.43
Net Income	-$37.92M	-$13.25M	$3.45B	$348.10M
7 Day Performance	12.18%	5.02%	3.39%	2.66%
1 Month Performance	1.56%	-2.12%	-0.72%	-0.85%
1 Year Performance	15.51%	61.49%	77.42%	23.96%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	1.3689 of 5 stars	$13.63 flat	$24.80 +82.0%	+15.5%	$468.19M	N/A	N/A	20	Gap Down
BCAX Bicara Therapeutics	1.343 of 5 stars	$26.10 +1.4%	$30.27 +16.0%	+175.1%	$1.71B	N/A	N/A	32	Upcoming Earnings
IMCR Immunocore	2.6641 of 5 stars	$33.24 +2.5%	$56.29 +69.3%	+6.3%	$1.69B	$400.02M	N/A	320	Earnings Report Analyst Forecast
SNDX Syndax Pharmaceuticals	2.5577 of 5 stars	$19.08 -0.8%	$42.55 +123.0%	+63.5%	$1.69B	$172.35M	N/A	110	Trending News Earnings Report Analyst Revision Gap Down
ZYME Zymeworks	2.869 of 5 stars	$22.79 +4.5%	$37.33 +63.8%	+95.8%	$1.66B	$105.96M	N/A	460	Earnings Report Analyst Forecast Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. BCAX, IMCR, SNDX, ZYME, and ANAB

How does Benitec Biopharma compare to Bicara Therapeutics?

Summary

How does Benitec Biopharma compare to Immunocore?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Summary

How does Benitec Biopharma compare to Zymeworks?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. BCAX, IMCR, SNDX, ZYME, and ANAB

How does Benitec Biopharma compare to Bicara Therapeutics?

Which has preferable valuation and earnings, BNTC or BCAX?

Does the media favor BNTC or BCAX?

Do insiders and institutionals hold more shares of BNTC or BCAX?

Is BNTC or BCAX more profitable?

Do analysts rate BNTC or BCAX?

Which has more volatility & risk, BNTC or BCAX?

Summary

How does Benitec Biopharma compare to Immunocore?

Do analysts prefer IMCR or BNTC?

Is IMCR or BNTC more profitable?

Which has more risk and volatility, IMCR or BNTC?

Which has preferable earnings and valuation, IMCR or BNTC?

Does the media refer more to IMCR or BNTC?

Do insiders and institutionals have more ownership in IMCR or BNTC?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Is SNDX or BNTC more profitable?

Do analysts recommend SNDX or BNTC?

Does the media favor SNDX or BNTC?

Which has more volatility and risk, SNDX or BNTC?

Do institutionals and insiders hold more shares of SNDX or BNTC?

Which has stronger valuation and earnings, SNDX or BNTC?

Summary

How does Benitec Biopharma compare to Zymeworks?

Do institutionals & insiders have more ownership in BNTC or ZYME?

Is BNTC or ZYME more profitable?

Which has higher valuation & earnings, BNTC or ZYME?

Does the media prefer BNTC or ZYME?

Do analysts prefer BNTC or ZYME?

Which has more risk and volatility, BNTC or ZYME?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Do institutionals and insiders believe in ANAB or BNTC?

Which has better valuation and earnings, ANAB or BNTC?

Which has more risk and volatility, ANAB or BNTC?

Is ANAB or BNTC more profitable?

Do analysts recommend ANAB or BNTC?

Does the media favor ANAB or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools